Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Pvt. Ltd.)
49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase - I
Bommasandra. Bengaluru - 560 099
Karnataka, India
CIN : L24233KA2006PLC039703
Tel : + 91 80 6672 4000
www.anthembio.com

Date: November 03, 2026

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Press Release on the Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2026

Dear Sir/Ma'am

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the Press Release on the Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026.

The same is also available on the Company's website at https://anthembio.com/

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(*Formerly known as Anthem Biosciences Private Limited*)

DIVYA PRASAD
Digitally signed by DIVYA PRASAD
Date: 2026.11.03 16:08:40 +05'30'

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

Press Release: Anthem Q2 & H1 FY27 Results

Consolidated Revenue from Operations for the quarter stood at ₹5,940 Mn.
EBITDA for the quarter was ₹3,304 Mn.
PAT at ₹2,115 Mn, with PAT margins at 32.4%.

For the first half, Consolidated Revenue from Operations was ₹10,123 Mn.
EBITDA for H1 FY27 was ₹5,059 Mn.
PAT at ₹3,314 Mn, with PAT margins at 30.2%.

Bengaluru, November 03, 2026: Anthem Biosciences Limited (BSE: 544449 | NSE: ANTHEM | INE0CZ201020), an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization ("CRDMO"), today announced unaudited results for the second quarter and half year ended September 30, 2026 as approved by its Board of Directors.

Q2 & H1 FY27 Financial Highlights:

Particulars (₹ Mn)	Q2FY27	Q2FY26	YoY	Q1FY27	QoQ	H1 FY27	H1 FY26	YoY
Revenue from Operations	**5,940**	**5,505**	***7.9%***	**4,182**	***42.0%***	**10,123**	**10,914**	***-7.2%***
CRDMO	5,093	4,662	*9.2%*	3,408	*49.4%*	8,501	9,195	*-7.6%*
Specialty Ingredients	848	843	*0.6%*	774	*9.5%*	1,622	1,718	*-5.6%*
Other Income	589	478	*23.3%*	249	*136.5%*	838	699	*19.9%*
Total Revenues	**6,529**	**5,983**	***9.1%***	**4,431**	*47.4%*	**10,960**	**11,613**	***-5.6%***
EBITDA	**3,304**	**2,661**	***24.1%***	**1,755**	***88.3%***	**5,059**	**4,805**	***5.3%***
Profit before tax before exceptional items	2,964	2,296	*29.1%*	1,446	*105.0%*	4,410	4,159	*6.0%*
Exceptional Items – impact of new labour code	n.a	n.a.	n.a.	n.a	n.a	n.a	n.a	*n.a*
Profit before tax after exceptional items	2,964	2,296	*29.1%*	1,446	*105.0%*	4,410	4,159	*6.0%*
Profit after tax	**2,115**	**1,734**	***21.9%***	**1,199**	***76.4%***	**3,314**	**3,092**	***7.2%***

H1 FY27 Key Financial Highlights:

- Consolidated Revenue from Operations was ₹10,123 Mn for the half year
  - *CRDMO business delivered ₹8,501 Mn revenues*
  - *Specialty Ingredients delivered ₹1,622 Mn revenues*
- EBITDA was ₹5,059 Mn, with EBITDA margins at 46.2%
  - *EBITDA for H1 FY27 includes Other Income of ₹838 Mn (H1 FY26: ₹699 Mn)*
    - *Other Operating Income on account of forex gain (net) is ₹70 Mn (H1 FY26: ₹340 Mn)*
    - *Financial and other Non-Operating Income is ₹768 Mn (H1 FY26: ₹359 Mn)*
- PAT (Profit After Tax) was ₹3,314 Mn, with PAT margins at 30.2%
- Net Cash position as of Sept 30, 2026, is ₹15,380 Mn

Q2FY27 Key Financial Highlights:

- Consolidated Revenue from Operations was ₹5,940 Mn for the quarter
  - *CRDMO business delivered ₹5,093 Mn revenues*
  - *Specialty Ingredients delivered ₹848 Mn revenues*
- EBITDA was ₹3,304 Mn, with EBITDA margins at 50.6%
  - *EBITDA for Q2FY27 includes Other Income of ₹589 Mn (Q2FY26: ₹478 Mn)*
    - *Other Operating Income on account of forex gain (net) is ₹58 Mn (Q2FY26: ₹304 Mn)*
    - *Financial and other Non-Operating Income is ₹531 Mn (Q2FY26: ₹174 Mn)*
- PBT was ₹2,964 Mn
- PAT (Profit After Tax) was ₹2,115 Mn, with PAT margins at 32.4%

Commenting on the results, **Ajay Bhardwaj, Chairman, Managing Director and CEO, Anthem Biosciences Limited, said:** *"We are pleased to report a robust performance for Q2FY27, driven by our CRDMO revenue stream. Underlying demand continues to remains strong and we are confident in our ability to sustain growth and create long-term value for all stakeholders. We expanded our EBITDA and PAT margins year-on-year. By maintaining strict discipline around cost efficiencies, yield optimization, and workforce productivity, we have further solidified our industry-leading margins, and are well-positioned to sustain this performance all year".*

Earnings Call:

Anthem Biosciences Limited will conduct earnings call at 12:30 pm (IST) on 4th November, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date and Time: 4th November, 2026, 12:30 pm (IST) / 2:00 am (EST) / 7:00 am (UK) / 3:00 pm (SGT/HKT)	
Universal Dial-in	+91 22 6280 1488 / +91 22 7115 8869
International Dial-in	Singapore: 8001012045 | HK: 800964448 | USA: 186674 62133 | UK: 08081011573
Diamond Pass link	Diamond Pass Registration

About Anthem: Incorporated in Bangalore on June 13, 2006, Anthem is an innovation-driven and technology-focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity ("NCE") and New Biological Entity ("NBE") capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. With the three pillars of innovation and technology, high quality standards, and a customer- first approach, Anthem is committed to solving problems in biology and chemistry using technology.

For more information, please visit https://anthembio.com/investors/

For further details, please feel free to contact: investors.abl@anthembio.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Anthem, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.